The Impact of Paediatric Obesity on Drug Pharmacokinetics: A Virtual Clinical Trials Case Study with Amlodipine

• Published in: Pharmaceutics 2024-04, Vol.16 (4), p.489
• Main Authors: Burhanuddin, Khairulanwar, Mohammed, Afzal, Badhan, Raj K S
• Format: Article
• Language: English
• Subjects: Age; Amlodipine; Body mass index; Case studies; Children; Clinical trials; Disease control; Drug dosages; Drug therapy; Enzymes; Health aspects; Medical research; Medicine, Experimental; Metabolism; Obesity; Obesity in children; paediatric; PBPK; Pediatric pharmacology; Pediatrics; Pharmacokinetics; Physiology; Proteins; Telmisartan
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics16040489

The incidence of paediatric obesity continues to rise worldwide and contributes to a range of diseases including cardiovascular disease. Obesity in children has been shown to impact upon the plasma concentrations of various compounds, including amlodipine. Nonetheless, information on the influence of obesity on amlodipine pharmacokinetics and the need for dose adjustment has not been studied previously. This study applied the physiologically based pharmacokinetic modelling and established a paediatric obesity population to assess the impact of obesity on amlodipine pharmacokinetics in children and explore the possible dose adjustments required to reach the same plasma concentration as non-obese paediatrics. The difference in predicted maximum concentration (C ) and area under the curve (AUC) were significant between children with and without obesity across the age group 2 to 18 years old when a fixed-dose regimen was used. On the contrary, a weight-based dose regimen showed no difference in C between obese and non-obese from 2 to 9 years old. Thus, when a fixed-dose regimen is to be administered, a 1.25- to 1.5-fold increase in dose is required in obese children to achieve the same C concentration as non-obese children, specifically for children aged 5 years and above.